A protein kinase D inhibitor suppresses AKT on T cells and antagonizes cancer immunotherapy by anti-PD-1

Keyphrases

• T Cells 100%
• Cancer Immunotherapy 100%
• Programmed Death-ligand 1 (PD-L1) 100%
• PD-1 Ligands 100%
• Protein Kinase D 100%
• PKD Inhibitors 60%
• Tumor Growth 20%
• Cancer Treatment 10%
• Tumor 10%
• Tumor-bearing Mice 10%
• Autoimmunity 10%
• Effector T Cells 10%
• Clinical Application 10%
• T Cell Infiltration 10%
• Inhibitory Effect 10%
• Mouse Tumor 10%
• Memory T Cells 10%
• Single Treatment 10%
• Therapeutic Effect 10%
• Small Molecule Inhibitors 10%
• Growth Signaling 10%
• T Cell Depletion 10%
• TCR Signaling 10%
• Akt Phosphorylation 10%
• Combination Therapy 10%
• T Cell Receptor Signaling 10%
• Anti-tumor Response 10%
• Immune-related Adverse Events 10%
• Micromolar Concentration 10%
• T Cell Exhaustion 10%
• Stem Cell Potential 10%
• T Cell Inactivation 10%
• Effector T Cell Response 10%
• CRT0066101 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Immunotherapy 100%
• Protein Kinase B 100%
• Protein Kinase D 100%
• Neoplasm 60%
• Tumor Growth 40%
• Combination Therapy 20%
• Adverse Event 20%
• T Lymphocyte Receptor 20%
• Therapeutic Effect 20%